CSPC Pharmaceutical Hong Kong | Sustainability Performance
Produces and distributes a wide range of pharmaceutical products including generic and branded drugs.
1994
China
10,001+ employees
Pharmaceuticals
$1B - 10B in revenue
$500M - 1B in profitability
Submit or report inaccurate dataDownload Company InsightsⓘBy downloading this report, you'll receive the most insightful and detailed analysis of the company's sustainability performance, compared to its peers. It includes key industry trends, carbon and energy intensity, nature impact, social metrics, and an in-depth look at key risks and controversies.
Sustainability Ranking & Industry Benchmark
#10587
Overallⓘ#692
in Chinaⓘ#252
in PharmaceuticalsⓘSustainability Maturity
ⓘSustainability Intent
ⓘOverview
Environmental
Carbon emissionsEnergy consumptionWater ManagementAir & land impactNature and biodiversitySocial
Diversity and InclusionPay GapsHealth and SafetyExternalitiesGovernance
SDG ImpactFinancial Data
Business performanceCapital & innovationAnalyst projections
Aligned
Aligned
Controversy level
- CSPC Pharmaceutical Group Limited, Hong Konglisted Chinese major pharma (NBP brain protection, Xuanning lipid), has faced sustained Chinese NMPA enforcement scrutiny including the contested 2024 sustained share price volatility amid Chinese VBP (volumebased procurement) tender pressure on CSPC's drug customer demand, plus periodic class actions over alleged inadequate disclosure affecting Hong Konglisted institutional shareholders amid Chinese pharma sector regulatory pressure.
